The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens

HIV Medicine

Volumn 17, Issue 1, 2016, Pages 46-55

  Casado, Jl ^a   Marin A ^a   Romero, V ^a   Banon S ^a   Moreno, A ^a   Perez Elías, Mj ^a   Moreno, S ^a   Rodriguez Sagrado, Ma ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiretroviral durability; HIV; Patient beliefs; Psychosocial; Satisfaction

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ATTITUDE TO HEALTH; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEPRESSION; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HEALTH BELIEF; HIV TREATMENT SATISFACTION QUESTIONNAIRE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT WITHDRAWAL; VIVID DREAM; ADVERSE EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PSYCHOLOGY; SATISFACTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PERSONAL SATISFACTION; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84955185102     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12280     Document Type: Article

References (44)

1. Collaboration of Observational HIVEREiE, Lewden C, Bouteloup V etal. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41: 433-445.
2. Panel de expertos de GeSIDA-PNS. [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. Enferm Infecc Microbiol Clin 2013; 31: e601-602 e698.
3. Thompson MA, Aberg JA, Hoy JF etal. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402.
4. Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS 2013; 27: 803-813.
5. Elzi L, Marzolini C, Furrer H etal. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170: 57-65.
6. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD, Investigators HIVOS. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617-1626.
7. Vo TT, Ledergerber B, Keiser O etal. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 1685-1694.
8. Jarrin I, Hernandez-Novoa B, Alejos B etal. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. Antivir Ther 2013: 161-170.
9. Imaz A, Olmo M, Penaranda M etal. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Antivir Ther 2013; 18: 125-130.
10. Smit M, Smit C, Cremin I, Garnett GP, Hallett T, de Wolf F. Could better tolerated HIV drug regimens improve patient outcome? AIDS 2012; 26: 1953-1959.
11. Cramer JA, Roy A, Burrell A etal. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
12. Trotta MP, Ammassari A, Melzi S etal. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S128-S131.
13. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7: 156-162.
14. Mocroft A, Youle M, Moore A etal. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185-194.
15. Wright Nunes JA, Wallston KA, Eden SK, Shintani AK, Ikizler TA, Cavanaugh KL. Associations among perceived and objective disease knowledge and satisfaction with physician communication in patients with chronic kidney disease. Kidney Int 2011; 80: 1344-1351.
16. Hayes RP, Fitzgerald JT. Perceptions and attitudes are primary contributors to insulin delivery system satisfaction in people with type 2 diabetes. Diabetes Technol Ther 2009; 11: 419-426.
17. Ammassari A, Trotta MP, Murri R etal. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S123-S127.
18. Preau M, Protopopescu C, Raffi F etal. Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability. AIDS Care 2012; 24: 434-443.
19. Roberts KJ. Physician-patient relationships, patient satisfaction, and antiretroviral medication Adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS 2002; 16: 43-50.
20. Marin A, Casado JL, Aranzabal L etal. Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res 2006; 15: 767-775.
21. Marín A, Casado JL, Aranzabal L etal. Impact of the lipodystrophy syndrome in adherence and attitudes toward antiretroviral drugs. 3th IAS Conference on HIV Pathogenesis and Treatment, July 2005, Río de Janeiro, Brazil. Abstract WePe12 7C34.
22. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004; 15: 38-44.
23. van Laerhoven H, van der Zaag-Loonen HJ, Derkx BH. A comparison of Likert scale and visual analogue scales as response options in children's questionnaires. Acta Paediatr 2004; 93: 830-835.
24. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 2003; 25: 277-283.
25. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001; 10: 517-531.
26. Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS 2005; 19: 9-18.
27. Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events. 2004. (Clarification August 2009). Available at: http://www.niaid.nih.gov (Accessed 31 March 2012).
28. Sherr L, Lampe F, Norwood S etal. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care 2008; 20: 442-448.
29. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000; 12: 387-398.
30. Siegel K, Lekas HM. AIDS as a chronic illness: psychosocial implications. AIDS 2002; 16 (Suppl 4): S69-S76.
31. Godin G, Cote J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care 2005; 17: 493-504.
32. Fehr JS, Nicca D, Sendi P etal. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33: 249-256.
33. Katz IT, Essien T, Marinda ET etal. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011; 25: 2177-2181.
34. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19: 124-133.
35. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23: 386-395.
36. Robison LS, Westfall AO, Mugavero MJ etal. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008; 24: 1347-1355.
37. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000; 283: 1329-1334.
38. INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA etal. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368: 287-298.
39. Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev 2012; 14: 168-178.
40. Willig JH, Abroms S, Westfall AO etal. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22: 1951-1960.
41. Di Biagio A, Prinapori R, Giannarelli D etal. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother 2013; 68: 200-205.
42. Scourfield A, Zheng J, Chinthapalli S etal. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012; 26: 1399-1401.
43. Davidson I, Beardsell H, Smith B etal. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res 2010; 86: 227-229.
44. Stone VE, Hogan JW, Schuman P etal. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr 2001; 28: 124-131.